Origin of aggressive ovarian cancer discovered

March 6, 2013, Cornell University

Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.

Pinpointing where this cancer originates has been difficult because 70 percent of patients are in advanced stages of disease by the time it is detected. Because the origin of ovarian carcinoma development is unknown, early have so far been unsuccessful.

Some epithelial cancers are known to occur in transitional zones between two types of epithelium (layers of tissue that line the body and organs and form ), while others originate in epithelial tissue . All organs have the capacity for regeneration, which is done by located in areas of each organ called stem cell niches.

With this knowledge, the researchers discovered a novel stem cell niche for the ovarian in mice and showed that ovarian carcinoma preferentially originates from stem cells found in that niche, according to the study published March 6 in the journal Nature. This stem cell niche lies in a transitional area known as the hilum region, a layer of cells that links the to the rest of the body.

"We now know where these cells are located in mice, so we can look in humans in those areas," said Alexander Nikitin, professor of pathology, leader of the Cornell Stem Cell Program and the paper's senior author. Andrea Flesken-Nikitin, a in Nikitin's lab, is the paper's lead author. The findings also provide a guide for scientists to look for stem cell niches and sources of cancer in other transitional zones in other organs, Nikitin added.

The researchers proved that stem cells from the hilum region were highly prone to ovarian carcinoma, using the most current genetic research techniques.

The researchers first found that cells in the hilum region express a known marker for stem cells, called ALDH1. They then isolated ALDH1 positive cells, sequenced their genetic profiles and found many markers previously reported for stem cells in other organs.

One of these markers, LGR5, has been studied for intestinal stem cells by other researchers who have bred special mice and developed an advanced method that uses a fluorescent protein to follow stem cells. The gene encoding the fluorescent protein is passed down from a stem cell to each generation of daughter cells, thereby marking the lineage. The technique "allows you to see the fate of stem cells over time," said Nikitin. Using the method on the hilum cells, "we showed that cells from the hilum area spread around the whole ovary."

Finally, the researchers microdissected ovary and hilum cells, inactivated two tumor suppressor genes p53 and Rb1, whose pathways are commonly altered in human aggressive ovarian , and injected cells into the abdominal cavity of mice. Very few tumors developed in the mice injected with ovary cells, but almost all of the mice injected with hilum cells died after developing aggressive, metastasizing cancers that were similar to human ovarian carcinomas.

In future work, the researchers will look for stem cells and sources of cancer in transitional zones in the human ovary and other organs, such as the stomach, rectum and uterine cervix.

Explore further: Cancer stem cells recruit normal stem cells to fuel ovarian cancer

More information: "Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche" appears online ahead of print March 6, 2013 in Nature. The authors are: Andrea Flesken-Nikitin, Chang-Il Hwang, Chieh-Yang Cheng, Tatyana V. Michurina, Grigori Enikolopov and Alexander Yu. Nikitin. The paper can be obtained at www.nature.org using the DOI: 10.1038/nature11979

Related Stories

Cancer stem cells recruit normal stem cells to fuel ovarian cancer

July 18, 2011
Researchers at the University of Michigan Comprehensive Cancer Center have found that a type of normal stem cell fuels ovarian cancer by encouraging cancer stem cells to grow.

New study reveals pigs could grow human organs

June 21, 2011
(PhysOrg.com) -- At the annual European Society of Human Genetics conference, a group of researchers presented their newly discovered technique that may soon enable pigs to grow human organs for transplant.

Researchers find cancer aggression differences in different types of prostate cells

February 25, 2013
(Medical Xpress)—A research team made up of representatives from several cancer research centers in the United States has found that cancers that develop in the prostate of mice may be either aggressive or sluggish depending ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.